ReviewUnited European gastroenterology journal2022
Treat-to-target and sequencing therapies in Crohn's disease.
Review in United European gastroenterology journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Recent advances in the management of small bowel Crohn's disease.The Korean journal of internal medicine · 2026Review
- Burden and Trends of Crohn's Disease Among Women of Reproductive Age in China, India, and the United States, 1990-2023, with Projections to 2040: A Systematic Analysis for the Global Burden of Disease Study 2023.International journal of women's health · 2026Article
- Targeting CXCL8 alleviates intestinal epithelial inflammation by suppressing the JAK-STAT pathway.European journal of medical research · 2025Article
- Combined Biologics and Exclusive Enteral Nutrition Promote Early Transmural Healing and Improve Long-Term Outcomes in Crohn's Disease: A Multicenter Retrospective Study.Clinical pharmacology and therapeutics · 2025Article
- Positioning and sequencing of advanced therapies in inflammatory bowel disease: A guide for clinical practice.World journal of gastroenterology · 2025Review
- Characterization of the Regulatory Landscape in Crohn's Disease Reveals microRNA-Associated Alterations that Shape Anti-TNF Response.Inflammatory bowel diseases · 2025Article
- NOD2 and Crohn's Disease Clinical Practice: From Epidemiology to Diagnosis and Therapy, Rewired.Inflammatory bowel diseases · 2025Review
- Diagnostic performance of intestinal ultrasound compared with CT enterography in Crohn's disease: single-center experience.Frontiers in medicine · 2025Article
- Managing Crohn's Disease Postoperative Recurrence Beyond Prophylaxis: A Comprehensive Review with Meta-Analysis.Biomedicines · 2024Review
- Comparative real-world outcomes between ustekinumab, infliximab, and adalimumab in bio-naïve and bio-experienced Crohn's disease patients: a retrospective multicenter study.BMC gastroenterology · 2024Article
- Proportion of inflammatory bowel diseases patients with suboptimal disease control in daily clinical practice-Real-world evidence from the inflammatory bowel diseases-podcast study.United European gastroenterology journal · 2024Article
- Integrating Omics into Functional Biomarkers of Type 1 Diabetes.Cold Spring Harbor perspectives in medicine · 2024Review
- The role of long non-coding RNA in Crohn's disease.Heliyon · 2024Review
- IBD-PODCAST Spain: A Close Look at Current Daily Clinical Practice in IBD Management.Digestive diseases and sciences · 2024Article
- Treat to target in Crohn's disease: A practical guide for clinicians.World journal of gastroenterology · 2024Review
- Crohn's disease management: translating STRIDE-II for UK clinical practice.Therapeutic advances in gastroenterology · 2024Review
- C-X-C Motif Chemokine 12 Was Identified as a Potential Gene Target in the Treatment of Crohn's Disease.International journal of general medicine · 2024Article
- Leaving behind the Mucosa: Advances and Future Directions of Intestinal Ultrasound in Ulcerative Colitis.Journal of clinical medicine · 2023Review
- Tapinarof cream 1% once daily for the treatment of adults with mild to severe plaque psoriasis: A novel topical therapy targeting the aryl hydrocarbon receptor.Journal of managed care & specialty pharmacy · 2023Review
- Benefits and Challenges of Treat-to-Target in Inflammatory Bowel Disease.Journal of clinical medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crohn's disease (CD) is a chronic immune-mediated inflammatory condition which can negatively impact a patient's quality of life. The traditional management strategy for CD has focused on symptomatic control, however, this approach fails to prevent organ damage and to change the progressive course of this disease. Thus, the field has moved towards a treat-to-target strategy that includes identifying individualized objective targets, choosing a therapy based on individual factors that include disease severity and risk, closely monitoring disease activity at predefined time points, and optimizing therapies as needed. Due to the increasing number of therapies approved for CD, this review explores the various factors which should be considered in the sequencing of treatment options together with using the treat-to-target framework to control disease activity early in its course and provide holistic patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.